The Medical Letter on Drugs and Therapeutics
ADVANCE
RELEASE
ARTICLE
June 17, 2025
View Complete Issue         Table of Contents 2019 
Onapgo ― An Apomorphine Subcutaneous Infusion for Parkinson's Disease
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Onapgo ― An Apomorphine Subcutaneous Infusion for Parkinson's Disease
June 17, 2025 (Issue: 5113)
Onapgo (Supernus), a solution for continuous subcutaneous infusion containing the dopamine agonist apomorphine, has been approved by the FDA for treatment of motor fluctuations in adults with advanced Parkinson's disease (PD)....more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Onapgo ― An Apomorphine Subcutaneous Infusion for Parkinson's Disease
Article code: 5113a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.